Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News EuroPCR 2023

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

Michael O'Riordan

May 17, 2023

News Conference News EuroPCR 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

Yael L. Maxwell

May 23, 2022

News Conference News EuroPCR 2020

ViV TAVR: New Durability and BASILICA Data Stress Need to Plan Ahead

Yael L. Maxwell

July 03, 2020

News Conference News EuroPCR 2019

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Michael O'Riordan

May 29, 2019

CHOICE: Better Hemodynamics, Less Structural Deterioration with CoreValve

News Conference News EuroPCR 2019

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Michael O'Riordan

May 24, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

News Conference News EuroPCR 2016

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Caitlin E. Cox

May 17, 2016

News Conference News EuroPCR 2015

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Yael L. Maxwell

May 20, 2015

Advertisement

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

ViV TAVR: New Durability and BASILICA Data Stress Need to Plan Ahead

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

More Early Stroke With SAVR Than TAVR in SURTAVI

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content